Cambridge Cancer Genomics
Nirmesh Patel is the Chief Scientific Officer of Cambridge Cancer Genomics, a smart genomics company using liquid biopsies to better guide cancer therapy choice and offer truly personalised medicine.
Trained as a biomedical scientist at King’s College London, he has 10 years of experience in oncology research and a PhD in Translational Cancer Medicine where he used data science and bioinformatics to identify novel targets in breast cancer and biomarkers to predict patient response, launching multiple drug discovery efforts in collaboration with pharma.
He has always sat at the interface between laboratory research, data science and the clinic and is unifying the three fields with a mission to improve cancer patient treatment.
Monitoring cancer evolution through smart genomics and liquid biopsies
One of the major advantages of liquid biopsies is the ability to probe the same patient multiple times with low invasiveness. Thus, allowing us to monitor the evolution of the tumour and identify markers that indicate response and resistance to therapy. Here we show how the analysis of the chronological mutational landscape of tumours can offer new therapeutic approaches for limiting tumour recurrence.
EVEN MORE SEMINARS
Philip Beer MRCP, FRCPath, PhD ONCODNA S.A
The evolution of oncology therapeutics in the genomic era.
Imran Liaquat MBChB BSc MedSci MRCS FRCS MEd Western General Hospital Edinburgh
Mylaine Riobe MD, FABOIM, FACOG Riobe Institute of Integrative Medicine
Cancer is not random! Evolving mechanisms for cancer causation and prevention
Profess Liz Ward Centre for Functioning and Health Research, Metro South Hospital and Health Service, and The Univers
Laryngectomy rehabilitation: Opportunities for improving speech pathology supports via telehealth
Dr Shreerang Bhide Royal Marsden Hospital
Circulating HPV DNA in Locally advanced head and neck cancer.